中国药房2012，Vol.23Issue(32)：3012-3014,3.DOI:10.6039/j.issn.1001-0408.2012.32.14
重组人血小板生成素治疗难治性原发免疫性血小板减少症的临床观察
Efficacy Observation of Recombinant Human Thrombopoietin for Refractory Primary Immune Thrombocytopenia
魏巍 1艾丽梅 2陶彩芳 1李雁1
作者信息
- 1. 辽宁医学院附属第三医院血液科,辽宁锦州121000
- 2. 辽宁医学院附属第一医院血液科,辽宁锦州121001
- 折叠
摘要
Abstract
OBJECTIVE: To observe the efficacy and ADR of recombinant human thrombopoietin (rhTPO) in the treatment of refractory primary immune thrombocytopenia. METHODS: 30 patients with refractory primary immune thrombocytopenia were administered with 300 U·kg-1 rhTPO subcutaneously once daily for 14 days at most or until the platelet count increased to 100×109/L. The platelet count, the function of liver and kidney and coagulation function were monitored. RESULTS: The platelet count (132.03 ± 70.37)×109/L 14 days after treatment was significantly greater than the platelet count (14.17 ± 6.74)×109/L before treatment (P<0.01). There were 23 patients in the group with completely response and 6 patients in the response group. Slight hyper-somnia and dizziness occurred in only 2 patients and they disappeared after withdrawal of rhTPO. No ADR was found in other patients. CONCLUSION: rhTPO has satisfactory efficacy in the treatment of refractory primary immune thrombocytopenia with slight ADR.关键词
重组人血小板生成素/难治性/免疫性血小板减少症Key words
Recombinant human thrombopoietin/ Refractory/ Immune thrombocytopenia分类
医药卫生引用本文复制引用
魏巍,艾丽梅,陶彩芳,李雁..重组人血小板生成素治疗难治性原发免疫性血小板减少症的临床观察[J].中国药房,2012,23(32):3012-3014,3.
